Roche has secured a European CE mark for its port delivery platform with ranibizumab, to be marketed as Contivue in the EU, while the Susvimo formulation remains under EMA review for neovascular age-related macular degeneration. The device-based platform comprises an implanted reservoir and dedicated ancillary tools for insertion, refill, and removal, designed to provide continuous intraocular delivery with as few as two refills per year. New seven-year data from the LADD ER program reinforce durability and functional stability, while prior Phase 3 data showed noninferior vision outcomes versus monthly intravitreal ranibizumab. In the United States, the combined device–drug is already approved for nAMD, diabetic macular edema, and diabetic retinopathy.
The strategic question is whether Europe’s retina ecosystem—patients, payers, and clinics—will pivot from episodic injections to a surgical, continuous delivery model. This is not a marginal convenience upgrade; it is an attempt to reset treatment workflows, economics, and adherence in a category where under-treatment erodes long-term vision. If adoption scales, Contivue could compress visit frequency, address capacity bottlenecks in high-volume clinics, and create a new competitive moat around Roche’s ophthalmology franchise.
Timing matters. Europe faces a swelling nAMD burden, with an estimated 1.7 million affected today and incidence rising as populations age. Even with extended-interval injectables, the real-world gap between label and practice remains stubborn, driving vision decline over time. Continuous delivery offers a different answer to the same problem: maintain pharmacologic pressure without demanding relentless clinic attendance. For patients, the benefit is fewer procedures and steadier control; for physicians, the trade is an upfront minor surgery and scheduled refills in exchange for fewer high-variability injection visits; for payers, the calculus shifts from per-injection costs to a device-plus-refill cycle that may be more predictable if outcomes hold.
Competitive dynamics will be sharp. High-dose aflibercept and faricimab have already extended intervals to 12–16 weeks for many patients, and biosimilars are reshaping price anchors. Contivue will need to carve out clinical segments where the implant’s durability and adherence advantage outweigh surgical and logistics hurdles—patients with high treatment burden, poor adherence risk, or those whose vision depends on consistent VEGF suppression. The seven-year extension data, while based on a modest cohort, help position the platform as a long-horizon solution. However, Medical Affairs teams will be expected to generate rigorous EU real-world evidence on safety, endothelial health, and device performance across varied practice settings to satisfy clinicians and assessors.
Market access will hinge on country-by-country mechanics. Coding for the implant procedure, refill economics, and site-of-service rules differ widely across EU markets. Health technology assessors will benchmark cost-effectiveness against not only monthly injections but also extended-interval agents and lower-priced biosimilars. Early uptake is likely to concentrate in surgical retina centers with established OR capacity and device experience, suggesting a hub-and-spoke diffusion pattern before broader community adoption. Roche’s signal that the port could be a platform for additional molecules points to a lifecycle strategy designed to lock in procedural and operational familiarity and defend share as gene therapies and next-generation implants advance.
The next milestone is the EMA decision on Susvimo for nAMD, which will determine if CE-marked hardware can translate into clinical use. If approved, the near-term test will be whether EU5 payers endorse a pricing and pathway model that rewards durable control over visit-based care. The broader industry question is whether drug–device convergence can become the default in retina before one-time or ultra–long-acting modalities mature—and whether Roche can scale Contivue fast enough to make continuous delivery the new standard rather than a niche alternative.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
